HOME >> BIOLOGY >> NEWS
Marathoning mice could have Olympian effects on obesity

A molecular switch known to regulate fat metabolism appears to prevent obesity and turns laboratory mice into marathon runners, a Salk Institute study has found.

The discovery of the switch could lead to treatments for obesity and disorders associated with it, such as heart disease and type 2 diabetes. The study, led by professor Ronald Evans and his postdoctoral fellow Yong-Xu Wang, appears in the September issue of the Public Library of Science Biology journal (PLoS Biology). Evans is also an Investigator of the Howard Hughes Medical Institute.

Evans, Wang and team discovered that activation of the switch, a receptor called PPAR-delta, increases the rate at which the body burns fat. This makes PPAR-delta an exciting potential target for drugs that treat diabetes and lipid disorders.

The team produced a genetically engineered mouse endowed with the activated form of PPAR-delta in its skeletal muscles. The result was a dramatic increase in "non-fatiguing" or "slow twitch" muscle cells and a mouse capable of running up to twice the distance of a normal littermate without training.

By expressing genes for an activated form of the receptor PPAR-delta, we created a mouse that could, compared to normal mice, run marathons, said Evans. The activated form of PPAR-delta produced muscle fibers that enhanced endurance exercise."

By turning on PPAR-delta, the team had produced highly efficient muscle fibers that burned fat more rapidly. As a result, the mice were almost unable to gain weight even in the absence of exercise.

"These muscles also provided resistance to obesity, despite the level of exercise," said Evans. "By manipulating this receptor, it is possible to design treatments that change our muscle makeup and help resist obesity and associated metabolic disorders.

To test the concept, Evans and his team treated normal mice with an experimental drug called GW501516 that activates PPAR-delta. These mice also expressed genes for
'"/>

Contact: Andrew Porterfield
porterfield@salk.edu
Salk Institute
24-Aug-2004


Page: 1 2

Related biology news :

1. Landmark agreement between Samoa and UC Berkeley could help search for AIDS cure
2. Circulation of disaster myths in Haiti could hinder appropriate disposal of bodies
3. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
4. Marijuana use could cause tubal pregnancies
5. Gene chips research in cotton could lead to superior variety
6. Groundbreaking research could ignite new solutions to heat transfer in nano-devices
7. Bullish chemical could repel yellow fever mosquitoes
8. Termites could hold the key to self-sufficient buildings
9. Wastewater could treat itself, power city
10. Sugar-coated sea urchin eggs could have sweet implications for human fertility
11. Identifying tick genes could halt disease, bioterrorism threat

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: